2020 ASCO Virtual Scientific Meeting*

Download All
May 29-31, 2020; Online at meetings.asco.org/am
Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the 2020 ASCO Annual Meeting.

Hematologic Malignancies

Slidesets Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies
Slidesets Enasidenib Plus Azacitidine vs Azacitidine Monotherapy in mIDH2 Newly Diagnosed Acute Myeloid Leukemia
Slidesets Phase Ib Study of Magrolimab Plus Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Slidesets AMG 330 Bispecific T-Cell Engager in Patients With R/R Acute Myeloid Leukemia: Update of First-in-Human Dose-Escalation Trial
Slidesets Phase III QUAZAR AML-001: Further Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR
Slidesets Phase III KEYNOTE-204: Pembrolizumab vs Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin Lymphoma
Slidesets ASPEN: Phase III Trial of Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Slidesets Phase I/II Trial of CD3 x CD20 Bispecific Antibody Epcoritamab (GEN3013) in R/R B-Cell NHL
Slidesets CheckMate-744: Nivolumab Plus Brentuximab Vedotin in Younger Patients With R/R Classical Hodgkin Lymphoma
Slidesets Acalabrutinib Monotherapy in Hematologic Malignancies: Updated Safety and Efficacy Results
Slidesets BOSTON: Phase III Trial of Weekly Selinexor, Bortezomib, and Dexamethasone Vs Twice Weekly Bortezomib and Dexamethasone in Pretreated Patients With Multiple Myeloma
Slidesets DREAMM-6: Belantamab Mafodotin Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slidesets Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma
Slidesets EVOLVE: Phase I/II Study of BCMA-Targeted CAR T-Cell Therapy Orvacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Slidesets STaMINA Long-term Follow-up: Post–Autologous Hematopoietic Cell Transplantation Strategies for Multiple Myeloma
Slidesets SWOG 1211: Phase I/II Trial of Elotuzumab + RVd vs RVd Alone in Newly Diagnosed, High-Risk Myeloma
Slidesets Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slidesets Phase III ENDURANCE: Carfilzomib/Len/Dex vs Bortezomib/Len/Dex in Newly Diagnosed Multiple Myeloma
Provided by Clinical Care Options, LLC.
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?